Drug Profile
Research programme: gene editing based therapeutics - Casebia Therapeutics
Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR TherapeuticsLatest Information Update: 09 May 2022
Price :
$50
*
At a glance
- Originator Casebia Therapeutics
- Class Antihaemorrhagics; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Gene therapies
- Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders
- Research Cancer; Haemophilia A; Retinitis pigmentosa
- No development reported Blindness; Congenital heart defects; Severe combined immunodeficiency
Most Recent Events
- 09 May 2022 Drug is still in research phase for Haemophilia A in USA
- 28 Apr 2022 CRISPR Therapeutics terminates Joint Venture Agreement for gene editing based therapeutics with Bayer
- 28 Feb 2022 The US Patent and Trademark Office issues decision in favor of Broad Institute for interference claim for patent related to CRISPR-Cas9 genome editing technology in USA